Prolactin and TSH response to TRH and metoclopramide before and after l-thyroxine therapy in subclinical hypothyroidism

Gaetano Lombardi, Mauro Iodice, Paolo Miletto, Bartolomeo Merola, Nicola Panza, Lucio Annunziato

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The effects of the dopamine (DA) receptor antagonist metoclopramide on the plasma thyroid stimulating hormone (TSH) and prolactin (PRL) levels were studied in 8 patients with subclinical hypothyroidism (defined as absence of clinical signs of hypothyroidism with normal thyroid hormone levels, normal or slightly increased basal plasma TSH levels and increased and long-lasting TSH response to TRH I before and after l-thyroxine replacement therapy. Metoclopramide induced a significant (p <0.01) TSH release in the subclinical hypothyroid patients. Two weeks after l-thyroxine replacement therapy (50 μg/day), the TSH response to metoclopramide was completely blunted in subclinical hypothyroidism. In these patients a significant (p <0.01) inhibition of TSH response to intravenous thyrotropin-releasing hormone (TRH) was also observed after treatment with thyroid hormone. In analogy to the TSH behavior, plasma PRL secretion in response to metoclopramide and TRH administration was significantly (p<0.05) inhibited in the subclinical hypothyroid patients after l-thyroxine replacement therapy.

Original languageEnglish
Pages (from-to)676-678
Number of pages3
JournalNeuroendocrinology
Volume43
Issue number6
DOIs
Publication statusPublished - 1986

Fingerprint

Metoclopramide
Thyrotropin-Releasing Hormone
Thyrotropin
Hypothyroidism
Thyroxine
Prolactin
Thyroid Hormones
Therapeutics
Dopamine Antagonists

Keywords

  • Metoclopramide
  • Prolactin
  • Subclinical hypothyroidism
  • Thyroid-stimulating hormone
  • Thyrotropin-releasing hormone

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Cellular and Molecular Neuroscience
  • Endocrine and Autonomic Systems
  • Neuroscience(all)

Cite this

Prolactin and TSH response to TRH and metoclopramide before and after l-thyroxine therapy in subclinical hypothyroidism. / Lombardi, Gaetano; Iodice, Mauro; Miletto, Paolo; Merola, Bartolomeo; Panza, Nicola; Annunziato, Lucio.

In: Neuroendocrinology, Vol. 43, No. 6, 1986, p. 676-678.

Research output: Contribution to journalArticle

Lombardi, Gaetano ; Iodice, Mauro ; Miletto, Paolo ; Merola, Bartolomeo ; Panza, Nicola ; Annunziato, Lucio. / Prolactin and TSH response to TRH and metoclopramide before and after l-thyroxine therapy in subclinical hypothyroidism. In: Neuroendocrinology. 1986 ; Vol. 43, No. 6. pp. 676-678.
@article{6ea4310f95a74fbe885f669d8b1ccaae,
title = "Prolactin and TSH response to TRH and metoclopramide before and after l-thyroxine therapy in subclinical hypothyroidism",
abstract = "The effects of the dopamine (DA) receptor antagonist metoclopramide on the plasma thyroid stimulating hormone (TSH) and prolactin (PRL) levels were studied in 8 patients with subclinical hypothyroidism (defined as absence of clinical signs of hypothyroidism with normal thyroid hormone levels, normal or slightly increased basal plasma TSH levels and increased and long-lasting TSH response to TRH I before and after l-thyroxine replacement therapy. Metoclopramide induced a significant (p <0.01) TSH release in the subclinical hypothyroid patients. Two weeks after l-thyroxine replacement therapy (50 μg/day), the TSH response to metoclopramide was completely blunted in subclinical hypothyroidism. In these patients a significant (p <0.01) inhibition of TSH response to intravenous thyrotropin-releasing hormone (TRH) was also observed after treatment with thyroid hormone. In analogy to the TSH behavior, plasma PRL secretion in response to metoclopramide and TRH administration was significantly (p<0.05) inhibited in the subclinical hypothyroid patients after l-thyroxine replacement therapy.",
keywords = "Metoclopramide, Prolactin, Subclinical hypothyroidism, Thyroid-stimulating hormone, Thyrotropin-releasing hormone",
author = "Gaetano Lombardi and Mauro Iodice and Paolo Miletto and Bartolomeo Merola and Nicola Panza and Lucio Annunziato",
year = "1986",
doi = "10.1159/000124603",
language = "English",
volume = "43",
pages = "676--678",
journal = "Neuroendocrinology",
issn = "0028-3835",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Prolactin and TSH response to TRH and metoclopramide before and after l-thyroxine therapy in subclinical hypothyroidism

AU - Lombardi, Gaetano

AU - Iodice, Mauro

AU - Miletto, Paolo

AU - Merola, Bartolomeo

AU - Panza, Nicola

AU - Annunziato, Lucio

PY - 1986

Y1 - 1986

N2 - The effects of the dopamine (DA) receptor antagonist metoclopramide on the plasma thyroid stimulating hormone (TSH) and prolactin (PRL) levels were studied in 8 patients with subclinical hypothyroidism (defined as absence of clinical signs of hypothyroidism with normal thyroid hormone levels, normal or slightly increased basal plasma TSH levels and increased and long-lasting TSH response to TRH I before and after l-thyroxine replacement therapy. Metoclopramide induced a significant (p <0.01) TSH release in the subclinical hypothyroid patients. Two weeks after l-thyroxine replacement therapy (50 μg/day), the TSH response to metoclopramide was completely blunted in subclinical hypothyroidism. In these patients a significant (p <0.01) inhibition of TSH response to intravenous thyrotropin-releasing hormone (TRH) was also observed after treatment with thyroid hormone. In analogy to the TSH behavior, plasma PRL secretion in response to metoclopramide and TRH administration was significantly (p<0.05) inhibited in the subclinical hypothyroid patients after l-thyroxine replacement therapy.

AB - The effects of the dopamine (DA) receptor antagonist metoclopramide on the plasma thyroid stimulating hormone (TSH) and prolactin (PRL) levels were studied in 8 patients with subclinical hypothyroidism (defined as absence of clinical signs of hypothyroidism with normal thyroid hormone levels, normal or slightly increased basal plasma TSH levels and increased and long-lasting TSH response to TRH I before and after l-thyroxine replacement therapy. Metoclopramide induced a significant (p <0.01) TSH release in the subclinical hypothyroid patients. Two weeks after l-thyroxine replacement therapy (50 μg/day), the TSH response to metoclopramide was completely blunted in subclinical hypothyroidism. In these patients a significant (p <0.01) inhibition of TSH response to intravenous thyrotropin-releasing hormone (TRH) was also observed after treatment with thyroid hormone. In analogy to the TSH behavior, plasma PRL secretion in response to metoclopramide and TRH administration was significantly (p<0.05) inhibited in the subclinical hypothyroid patients after l-thyroxine replacement therapy.

KW - Metoclopramide

KW - Prolactin

KW - Subclinical hypothyroidism

KW - Thyroid-stimulating hormone

KW - Thyrotropin-releasing hormone

UR - http://www.scopus.com/inward/record.url?scp=0022913121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022913121&partnerID=8YFLogxK

U2 - 10.1159/000124603

DO - 10.1159/000124603

M3 - Article

C2 - 3093910

AN - SCOPUS:0022913121

VL - 43

SP - 676

EP - 678

JO - Neuroendocrinology

JF - Neuroendocrinology

SN - 0028-3835

IS - 6

ER -